Evaluating a new method to measure tumor sugar consumption using PET imaging
Evaluation of the Fractional Uptake Rate (FUR) in 18F-FDG PET/CT to Assess Tumour Metabolic Activity
This study is testing a new way to measure how much sugar tumors use by comparing a new method with a standard scan in people with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Academisch Ziekenhuis Maastricht Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Maastricht, Limburg) |
| Trial ID | NCT05654675 on ClinicalTrials.gov |
What this trial studies
This study aims to assess a novel approach for quantifying glucose consumption in tumors using PET/CT imaging. Participants will undergo a standard FDG PET/CT scan along with a dynamic PET/CT scan to evaluate the effectiveness of the fractional uptake rate (FUR) compared to the traditional standardized uptake value (SUV). Blood samples will be collected at three time points during the examination to support the analysis. The goal is to determine if the FUR provides a more accurate assessment of tumor metabolism than the SUV, which has known limitations.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 or older who are scheduled to receive an 18F FDG PET/CT scan as part of their standard care.
Not a fit: Patients with diabetes, recent physical exercise, or those who have undergone prior cancer treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to more accurate assessments of tumor metabolism, improving treatment decisions for patients with lung cancer and lymphoma.
How similar studies have performed: While the approach of using FUR is innovative, similar pharmacokinetic modeling methods have shown promise in other studies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who receive an 18F FDG PET/CT scan as part of standard care * Be competent and be 18 years of age or older Exclusion Criteria: * Diabetes (fasted blood glucose \> 7 mmol/L) * Not fasted \> 4 hours * Physical exercise within 24 hours * Earlier treatment for carcinoma with radio/chemo-therapy * Active inflammation (fever \> 38 degrees, CRP \> 5) * Any condition or medical indication (such as claustrophobia) that indicates that the patient will not be able to lie still for the duration of the dynamic PET/CT examination * Pregnant or breast feeding
Where this trial is running
Maastricht, Limburg
- Academisch ziekenhuis Maastricht — Maastricht, Limburg, Netherlands (Recruiting)
Study contacts
- Principal investigator: Roel Wierts, PhD — Medical physicist
- Study coordinator: Sam Springer, MSc
- Email: sam.springer@mumc.nl
- Phone: +31433874907
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.